A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Capsaicin (Primary)
- Indications Osteoarthritis; Pain
- Focus Therapeutic Use
- Sponsors Propella Therapeutics
Most Recent Events
- 22 Jun 2020 New trial record
- 02 Jun 2020 According to a Vizuri Health Sciences media release, results from this trial were recognized by the American College of Rheumatology.